Ferroptosis and non-coding RNAs in lung cancer: exploring molecular mechanisms and diagnostic/therapeutic implications.

IF 6 2区医学 Q1 ONCOLOGY

Cancer Cell International Pub Date : 2025-10-21 DOI:10.1186/s12935-025-03949-x

Hedong Xue, Melika Malek, Liangyu Li

{"title":"Ferroptosis and non-coding RNAs in lung cancer: exploring molecular mechanisms and diagnostic/therapeutic implications.","authors":"Hedong Xue, Melika Malek, Liangyu Li","doi":"10.1186/s12935-025-03949-x","DOIUrl":null,"url":null,"abstract":"<p><p>Lung cancer is the second most prevalent type of cancer on a global scale, and is widely known for being the deadliest. Revealing the fundamental molecular mechanisms of this condition has the potential to unlock fresh possibilities and avenues for managing it. Ferroptosis is a newly discovered type of controlled cell death that distinguishes itself from traditional forms of programmed cell death, specifically apoptosis and necrosis, through its distinct biochemical and structural characteristics. Changes made to the mechanism that regulates ferroptosis can have a significant influence on the development of various illnesses, such as, though not limited to, lung cancer. Based on scientific studies, it has been proven that cancer cells possess a significant capability to inhibit ferroptosis, leading to their continuous growth and survival. The presence of non-coding RNAs has a profound influence on controlling a wide range of cellular functions, with a particular focus on cancer. They have been closely associated with all key features of lung cancer. Fresh findings have indicated that these particles also have the task of controlling ferroptosis. Thus, the use of non-coding RNA as a therapeutic strategy offers a potentially effective option for regulating ferroptosis in the management of cancer. The main focus of this overview is on ncRNAs and their function in controlling ferroptosis, specifically within the context of lung cancer.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"364"},"PeriodicalIF":6.0000,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-025-03949-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lung cancer is the second most prevalent type of cancer on a global scale, and is widely known for being the deadliest. Revealing the fundamental molecular mechanisms of this condition has the potential to unlock fresh possibilities and avenues for managing it. Ferroptosis is a newly discovered type of controlled cell death that distinguishes itself from traditional forms of programmed cell death, specifically apoptosis and necrosis, through its distinct biochemical and structural characteristics. Changes made to the mechanism that regulates ferroptosis can have a significant influence on the development of various illnesses, such as, though not limited to, lung cancer. Based on scientific studies, it has been proven that cancer cells possess a significant capability to inhibit ferroptosis, leading to their continuous growth and survival. The presence of non-coding RNAs has a profound influence on controlling a wide range of cellular functions, with a particular focus on cancer. They have been closely associated with all key features of lung cancer. Fresh findings have indicated that these particles also have the task of controlling ferroptosis. Thus, the use of non-coding RNA as a therapeutic strategy offers a potentially effective option for regulating ferroptosis in the management of cancer. The main focus of this overview is on ncRNAs and their function in controlling ferroptosis, specifically within the context of lung cancer.

查看原文本刊更多论文

肺癌中的铁下垂和非编码rna：探索分子机制和诊断/治疗意义。

肺癌是全球范围内第二常见的癌症，也是众所周知的最致命的癌症。揭示这种情况的基本分子机制有可能解锁新的可能性和途径来管理它。Ferroptosis是一种新发现的受控细胞死亡类型，通过其独特的生化和结构特征，将其与传统形式的程序性细胞死亡（特别是凋亡和坏死）区分开来。调节铁下垂的机制发生变化，可能对各种疾病的发展产生重大影响，例如肺癌（但不限于肺癌）。科学研究证明，癌细胞具有显著的抑制铁下垂的能力，使其能够持续生长和存活。非编码rna的存在对控制广泛的细胞功能具有深远的影响，特别是对癌症的影响。它们与肺癌的所有关键特征密切相关。新的研究结果表明，这些颗粒也有控制铁下垂的任务。因此，使用非编码RNA作为一种治疗策略，为癌症治疗中调节铁下垂提供了一种潜在的有效选择。本综述的主要重点是ncrna及其在控制铁下垂中的功能，特别是在肺癌的背景下。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.